News & AnalysisVibrant nabs $7.5m Series EVibrant, a developer of gastrointestinal treatments, has secured $7.5 million in Series E funding.ByIris Dorbian26 March 2021•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs